Biopharmaceutical company Acceleron Pharma Inc (NASDAQ:XLRN) revealed on Thursday the appointment of Robert K. Zeldin, MD as its chief medical officer. (CMO).
In the medical department, Dr Zeldin succeeds the company's outgoing CMO, Matthew Sherman, MD, who will continue until the anticipated mid-2018 release of topline Phase 3 data from the BELIEVE trial of luspatercept in beta-thalassemia patients and will then serve in an advisory capacity for one year thereafter.
Most recently, Dr Zeldin was a member of the Executive Committee as well as chief medical officer of Belgium-based Ablynx NV.
Previously, Dr Zeldin has served as senior vice president and head of Global Clinical Development at French pharmaceutical firm Stallergenes SA, vice president and US medical franchise head, Respiratory and Dermatology at Novartis Pharmaceuticals, as well as senior director, Clinical Development at Merck.
At the start of his career, Dr. Zeldin was employed as a medical officer at the US Food & Drug Administration's Center for Biologics Evaluation and Research, assessing efficacy and safety data from the clinical development of allergy-related therapies, vaccines and orphan products.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review